| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Published online before print December 12, 2008
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




From the Department of Molecular Pharmacology and Physiology,* Johnnie B. Byrd Sr. Alzheimers Institute, University of South Florida, Tampa, Florida; the Department of Neuroscience,
Mayo Clinic Jacksonville, Jacksonville, Florida; the Reta Lila Weston Institute,
University College London Institute of Neurology, London, United Kingdom; and the Department of Cell and Molecular Biology,
Northwestern University, Chicago, Illinois
We have extensively analyzed the biochemical and histochemical profiles of the tau protein from the rTg4510 transgenic mouse model in which the animals uniquely develop forebrain tau pathologies similar to those found in human tauopathies. Levels of several soluble phosphorylated tau species were highest at 1 month relative to later time points, suggesting that certain tau hyperphosphorylation events were insufficient to drive tangle formation in young mice. Despite a robust, pre-tangle-like accumulation of phospho-tau in 1-month-old mice, this material was cleared by 3 months, indicating that the young mouse brain either fails to facilitate tau insolubility or possesses an enhanced ability to clear tau relative to the adult. We also found that while heat shock protein expression increased with normal aging, this process was accelerated in rTg4510 mice. Moreover, by exploiting an exon 10 (–) specific antibody, we demonstrated that endogenous mouse tau turnover was slowed in response to human tau over-expression, and that this endogenous tau adopted disease-related properties. These data suggest that a younger brain fails to develop lasting tau pathology despite elevated levels of phosphorylated tau, perhaps because of reduced expression of stress-related proteins. Moreover, we show that the active production of small amounts of abnormal tau protein facilitates dysfunction and accumulation of otherwise normal tau, a significant implication for the pathogenesis of patients with Alzheimers disease.
This article has been cited by other articles:
![]() |
U. K. Jinwal, J. Koren III, S. I. Borysov, A. B. Schmid, J. F. Abisambra, L. J. Blair, A. G. Johnson, J. R. Jones, C. L. Shults, J. C. O'Leary III, et al. The Hsp90 Cochaperone, FKBP51, Increases Tau Stability and Polymerizes Microtubules J. Neurosci., January 13, 2010; 30(2): 591 - 599. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |